Trial reportJournal of clinical microbiology2006
Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints.
Trial report in Journal of clinical microbiology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 94 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
94 citing papers in PubMed.
- Co-Administration with Voriconazole Doubles the Exposure of Ruxolitinib in Patients with Hematological Malignancies.Drug design, development and therapy · 2022Trial
- Intravenous anidulafungin followed optionally by oral voriconazole for the treatment of candidemia in Asian patients: results from an open-label Phase III trial.BMC infectious diseases · 2013Trial
- Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism.European journal of clinical pharmacology · 2010Trial
- Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods.Antimicrobial agents and chemotherapy · 2007Trial
- Article
- Formulation Studies on Microemulsion-Based Polymer Gels Loaded with Voriconazole for the Treatment of Skin Mycoses.Pharmaceutics · 2025Article
- Variations in virulence factors, antifungal susceptibility and extracellular polymeric substance compositions of cryptic and uncommon Candida species from oral candidiasis.BMC oral health · 2025Article
- Phenotypical Differences at the Physiological and Clinical Level between Two Genetically Closely RelatedJournal of fungi (Basel, Switzerland) · 2024Article
- Commercial Methods for Antifungal Susceptibility Testing of Yeasts: Strengths and Limitations as Predictors of Resistance.Journal of fungi (Basel, Switzerland) · 2022Review
- Epidemiology and Prevalence of Oral Candidiasis in HIV Patients From Chad in the Post-HAART Era.Frontiers in microbiology · 2022Article
- Antifungal Susceptibility Testing: A Primer for Clinicians.Open forum infectious diseases · 2021Review
- Toward Harmonization of Voriconazole CLSI and EUCAST Breakpoints for Candida albicans Using a ValidatedAntimicrobial agents and chemotherapy · 2020Article
- AreJournal of clinical microbiology · 2018Review
- Bioactive nano-metal-organic frameworks as antimicrobials against Gram-positive and Gram-negative bacteria.Toxicology research · 2018Article
- Interpersonal Factors in the Pharmacokinetics and Pharmacodynamics of Voriconazole: Are CYP2C19 Genotypes Enough for Us to Make a Clinical Decision?Current drug metabolism · 2018Review
- Activity of Combined Antifungal Agents Against Multidrug-Resistant Candida glabrata Strains.Mycopathologia · 2017Article
- Oral candidiasis among African human immunodeficiency virus-infected individuals: 10 years of systematic review and meta-analysis from sub-Saharan Africa.Journal of oral microbiology · 2017Review
- Therapeutic Drug Monitoring of Voriconazole in the Management of Invasive Fungal Infections: A Critical Review.Clinical pharmacokinetics · 2015Review
- SUSCEPTIBILITY TEST FOR FUNGI: CLINICAL AND LABORATORIAL CORRELATIONS IN MEDICAL MYCOLOGY.Revista do Instituto de Medicina Tropical de Sao Paulo · 2015Review
- Distribution of yeast isolates from invasive infections and their in vitro susceptibility to antifungal agents: evidence from 299 cases in a 3-year (2010 to 2012) surveillance study.Mycopathologia · 2015Observational
34 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
14 authors.
Funding
Abstract
Developing interpretive breakpoints for any given organism-drug combination requires integration of the MIC distribution, pharmacokinetic and pharmacodynamic parameters, and the relationship between the in vitro activity and outcome from both in vivo and clinical studies. Using data generated by standardized broth microdilution and disk diffusion test methods, the Antifungal Susceptibility Subcommittee of the Clinical and Laboratory Standards Institute has now proposed interpretive breakpoints for voriconazole and Candida species. The MIC distribution for voriconazole was determined using a collection of 8,702 clinical isolates. The overall MIC90 was 0.25 microg/ml and 99% of the isolates were inhibited at < or = 1 microg/ml of voriconazole. Similar results were obtained for 1,681 Candida isolates (16 species) from the phase III clinical trials. Analysis of the available data for 249 patients from six phase III voriconazole clinical trials demonstrated a statistically significant correlation (P = 0.021) between MIC and investigator end-of-treatment assessment of outcome. Consistent with parallel pharmacodynamic analyses, these data support the following MIC breakpoints for voriconazole and Candida species: susceptible (S), < or = 1 microg/ml; susceptible dose dependent (SDD), 2 microg/ml; and resistant (R), > or = 4 microg/ml. The corresponding disk test breakpoints are as follows: S, > or = 17 mm; SDD, 14 to 16 mm; and R, < or = 13 mm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.